SXTC

China SXT Pharmaceuticals, Inc. (SXTC) SWOT Analysis Analysis (2026)

Invetso Score: 1.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.4 (Weak)

High current and quick ratios indicate near-term liquidity coverage versus peers, but they do not offset the company’s structurally poor capital efficiency.

The reported debt-to-equity ratio is low, which reduces balance-sheet leverage relative to more indebted peers and limits refinancing pressure.

A positive liquidity buffer can support operations through working-capital volatility, giving SXTC more short-term flexibility than tighter-liquidity competitors.

Weaknesses

Score:

Negative ROIC shows invested capital is destroying value, leaving SXTC structurally behind profitable peers that compound returns above their cost of capital.

The cash conversion cycle above 1,100 days indicates severe working-capital inefficiency, far worse than peers and a direct drag on liquidity and margins.

Net debt to EBITDA is elevated despite weak earnings generation, implying leverage is burdensome relative to peers with stronger cash flow coverage.

The absence of reported operating and gross margins suggests limited evidence of durable unit economics, which weakens SXTC versus peers with clearer profitability profiles.

Opportunities

Score:

Working-capital normalization could materially improve cash generation because SXTC’s extreme cash conversion cycle leaves more room for operational peers to outperform on liquidity.

If management improves asset turnover and inventory discipline, the company could narrow the gap with peers that convert capital into revenue more efficiently.

Any stabilization in profitability metrics would have outsized relative impact because SXTC starts from a very weak return base versus established competitors.

Threats

Score:

Persistent negative returns on invested capital increase the risk that peers continue compounding value while SXTC remains trapped in value-destructive capital allocation.

A prolonged cash conversion cycle can force additional financing or operational strain, leaving SXTC more vulnerable than peers with faster cash generation.

If creditors or suppliers tighten terms, SXTC’s weak earnings quality and slow cash recovery could amplify stress relative to better-capitalized competitors.

Overall Score

Score:

SXTC is structurally weak versus peers because negative capital returns and extreme working-capital inefficiency outweigh its short-term liquidity cushion.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on China SXT Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →